CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arbutus Biopharma Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arbutus Biopharma Corp
100-8900 Glenlyon Parkway
Phone: (604) 419-3200p:604 419-3200 BURNABY, BC  V5J 5J8  Canada Ticker: ABUSABUS

Business Summary
Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Frank M.Torti 40 11/1/2018 11/1/2018
President, Chief Executive Officer, Director William H.Collier 6/24/2019 6/24/2019
Chief Financial Officer David C.Hastings 57 6/11/2018 6/11/2018
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
OnCore Biopharma, Inc. 3805 Old Easton Road Doylestown PA United States

Business Names
Business Name
ABUS
Arbutus Biopharma Inc.
Arbutus Biopharma US Holdings, Inc.
OnCore Biopharma, Inc.
TKM Acquisition Corporation

General Information
Number of Employees: 80 (As of 12/31/2018)
Outstanding Shares: 56,850,172 (As of 10/31/2019)
Shareholders: 102
Stock Exchange: NASD
Federal Tax Id: 980597776
Fax Number: (604) 419-3201


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 19, 2019